Patents by Inventor Wenting Luo

Wenting Luo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LINKER FOR ANTIBODY-DRUG CONJUGATES AND ITS USE
    Publication number: 20250145731
    Abstract: The present invention provides a linker for preparing antibody-drug conjugates and antibody-drug conjugates prepared by the linker, as well as use of the antibody-drug conjugates in a medicament for treating tumor. The linker is capable of coupling simultaneously with the thiol group or amino group on the antibody or functional fragment of the antibody, especially it is capable of coupling with 2, 3 or 4 thiol groups on the antibody or functional fragment of the antibody. A coupled product is uniform and structurally stable.
    Type: Application
    Filed: November 19, 2024
    Publication date: May 8, 2025
    Applicant: RemeGen Co., Ltd.
    Inventors: Changjiang Huang, Hui Ye, Hu Chen, Xiuzhi Zhan, Nan Shen, Wenting Luo, Qiaohua Hou, Jianmin Fang
  • ANTI-MESOTHELIN ANTIBODY AND ANTIBODY DRUG CONJUGATE THEREOF
    Publication number: 20250090682
    Abstract: The present invention discloses an antibody drug conjugate that targets MSLN. The present invention also disclosed a method of making the antibody drug conjugate (ADC). The present invention further discloses a novel MSLN antibody or a functional fragment thereof comprising engineered heavy and light chains.
    Type: Application
    Filed: November 13, 2024
    Publication date: March 20, 2025
    Applicant: RemeGen, Ltd.
    Inventors: Jianmin Fang, Changjiang Huang, Jing Jiang, Hui Ye, Shenjun Li, Qiaoyu Xu, Wenting Luo, Mingxue Wang
  • Linker for antibody-drug conjugates and its use
    Patent number: 12195552
    Abstract: The present invention provides a linker for preparing antibody-drug conjugates and antibody-drug conjugates prepared by the linker, as well as use of the antibody-drug conjugates in a medicament for treating tumor. The linker is capable of coupling simultaneously with the thiol group or amino group on the antibody or functional fragment of the antibody, especially it is capable of coupling with 2, 3 or 4 thiol groups on the antibody or functional fragment of the antibody. A coupled product is uniform and structurally stable.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: January 14, 2025
    Assignee: RemeGen Co., Ltd.
    Inventors: Changjiang Huang, Hui Ye, Hu Chen, Xiuzhi Zhan, Nan Shen, Wenting Luo, Qiaohua Hou, Jianmin Fang
  • Anti-mesothelin antibody and antibody drug conjugate thereof
    Patent number: 12171840
    Abstract: The present invention discloses an antibody drug conjugate that targets MSLN. The present invention also disclosed a method of making the antibody drug conjugate (ADC). The present invention further discloses a novel MSLN antibody or a functional fragment thereof comprising engineered heavy and light chains.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: December 24, 2024
    Assignee: RemeGen, Ltd.
    Inventors: Jianmin Fang, Changjiang Huang, Jing Jiang, Hui Ye, Shenjun Li, Qiaoyu Xu, Wenting Luo, Mingxue Wang
  • PHARMACEUTICAL COMBINATION AND USE THEREOF
    Publication number: 20240189341
    Abstract: The present disclosure provides a pharmaceutical combination and use thereof. By using an effective amount of methyl-?-cyclodextrin as a preparation component or a combined auxiliary drug, the efficacy of ADC can be significantly improved, so that some of the ADC drugs with safety issues caused by excessive dosage can be developed. Moreover, due to the reduction in the dosage of ADC drugs, the cost of production and the cost of treatment for patients have also been greatly reduced, thereby being beneficial.
    Type: Application
    Filed: June 21, 2022
    Publication date: June 13, 2024
    Inventors: Xinling ZHANG, Wenting LUO, Yue WANG, Jie ZHOU, Qilin YIN, Changjiang HUANG, MARIE M. ZHU
  • ANTI-C-MET ANTIBODY-DRUG CONJUGATE AND APPLICATIONS THEREOF
    Publication number: 20240165253
    Abstract: The present disclosure relates to the technical field of c-Met antibody drugs, specifically to a c-Met-targeted antibody-drug conjugate and applications thereof. The antibody-drug conjugate of the present disclosure comprises an antibody conjugated with one or more therapeutic agents or antigen-binding fragments of the antibody, is able to effectively inhibit the growth of a tumor tissue, provides a significant inhibitory effect with respect to c-Met-positive cancer, and has excellent safety.
    Type: Application
    Filed: August 31, 2021
    Publication date: May 23, 2024
    Inventors: Jianmin FANG, Changjiang HUANG, Xuejing YAO, Wenting LUO
  • ANTI-CLAUDIN 18.2 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF
    Publication number: 20230272109
    Abstract: Provided are an antibody targeting Claudin 18.2, an antibody-drug conjugate, and use thereof in treatment of cancer. Also provided are a nucleotide encoding the Claudin 18.2 antibody, a polynucleotide combination, an expression vector, an expression vector combination, a pharmaceutical composition comprising the Caudill 18.2 antibody and the antibody-drug conjugate, and an application thereof in preparation of a medication for treatment or prevention of cancer.
    Type: Application
    Filed: May 7, 2022
    Publication date: August 31, 2023
    Inventors: Jianmin FANG, Yuanhao LI, Marie M. ZHU, Jing JIANG, Yuelei SHEN, Shenjun LI, Wenting LUO, Xiaoping ZHANG, Lili WANG, Ling WANG, Qinbin ZHANG, Fang YANG
  • LINKER FOR ANTIBODY-DRUG CONJUGATES AND ITS USE
    Publication number: 20220072137
    Abstract: The present invention provides a linker for preparing antibody-drug conjugates and antibody-drug conjugates prepared by the linker, as well as use of the antibody-drug conjugates in a medicament for treating tumor. The linker is capable of coupling simultaneously with the thiol group or amino group on the antibody or functional fragment of the antibody, especially it is capable of coupling with 2, 3 or 4 thiol groups on the antibody or functional fragment of the antibody. A coupled product is uniform and structurally stable.
    Type: Application
    Filed: December 13, 2019
    Publication date: March 10, 2022
    Applicant: RemeGen Co., Ltd.
    Inventors: Changjiang Huang, Hui Ye, Hu Chen, Xiuzhi Zhan, Nan Shen, Wenting Luo, Qiaohua Hou, Jianmin Fang
  • ANTI-MESOTHELIN ANTIBODY AND ANTIBODY DRUG CONJUGATE THEREOF
    Publication number: 20220056147
    Abstract: The present invention discloses an antibody drug conjugate that targets MSLN. The present invention also disclosed a method of making the antibody drug conjugate (ADC). The present invention further discloses a novel MSLN antibody or a functional fragment thereof comprising engineered heavy and light chains.
    Type: Application
    Filed: May 15, 2019
    Publication date: February 24, 2022
    Applicant: Remegen, Ltd.
    Inventors: Jianmin Fang, Changjiang Huang, Jing Jiang, Hui Ye, Shenjun Li, Qiaoyu Xu, Wenting Luo, Mingxue Wang
  • METHODS OF ISOLATING RNA AND MAPPING OF POLYADENYLATION ISOFORMS
    Publication number: 20140329700
    Abstract: The invention relates to compositions and methods to isolate nucleic acids, and the identification of polyadenylation sites in a gene of interest. In one aspect, the invention provides an oligonucleotide comprising at least one nucleic acid and an affinity moiety, wherein said nucleic acid is 30-60 nucleotides in length and said nucleic acid comprises 1-25 uracil and 5-50 thymine nucleotides.
    Type: Application
    Filed: August 23, 2012
    Publication date: November 6, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Bin Tian, Wenting Luo, Zhe Ji, Mainul Hoque